CROI 2020 Program and Conference Information

Oral Sessions

149 HIGHHIV INCIDENCE IN YOUNGWOMEN IN THE BOTSWANA COMBINATION PREVENTION PROJECT Faith Ussery , Pamela J. Bachanas, Mary Grace Alwano, Refeletswe Lebelonyane, Lisa Block, Kathleen Wirth, Gene Ussery, Baraedi W. Sento, T endani Gaolathe, Etienne Kadima, William Abrams, Shahin Lockman, Janet Moore 150 RAPIDLY DECLINING HIV INCIDENCE AMONGMEN ANDWOMEN IN RAKAI, UGANDA Gertrude Nakigozi, Larry W. Chang, Steven J. Reynolds, Fred Nalugoda, Godfrey Kigozi, Thomas C. Quinn, Ronald H. Gray, Alice Kisakye, Anthony Ndyanabo, Robert Ssekubugu, David Serwadda, Maria Wawer, Joseph Kagaayi, Mary K. Grabowski , for the Rakai Health Sciences Program 151 INCREASED OVERALL LIFE EXPECTANCY BUT NOT COMORBIDITY- FREE YEARS FOR PEOPLEWITHHIV Julia L. Marcus , Wendy Leyden, Alexandra N. Anderson, Rulin Hechter, Michael A. Horberg, Haihong Hu, Jennifer O. Lam, William J. Towner, Qing Yuan, Michael J. Silverberg 152 LOW-LEVEL VIREMIA DURING ART AND THE RISK OF DEATH, AIDS, AND SERIOUS NON-AIDS EVENTS Olof Elvstam , Gaetano Marrone, Patrik Medstrand, Carl Johan Treutiger, Anders Sönnerborg, Magnus Gisslén, Per Bjorkman Themed Discussion TD-11 THE ROAD TO A BETTER VACCINE: CLINICAL TRIALS AND COHORT STUDIES Room 312 1:30 PM - 2:30 PM Themed Discussion Leader Richard A. Koup , National Institutes of Health, Bethesda, MD, USA 11:15 11:30 11:45 11:00 THE RV144VACCINE PRIMED IgG4 ANDV1V2-ADCP RESPONSES INHIV BREAKTHROUGH INFECTIONS Thembi Mdluli , Dominic Paquin-Proulx, Bonnie Slike, Gina Donofrio, Sorachai Nitayaphan, Punnee Pitisutthithum, Supachai Rerks-Ngarm, Margaret Ackerman, Merlin L. Robb, Nelson L. Michael, Sandhya Vasan, Michael A. Eller, Shelly J. Krebs, Morgane Rolland, for the RV144 study group PHASE I/II A TRIAL OF HIV CLADE C DNAWITHMF59- OR AS01B- ADJUVANTED CLADE C PROTEIN Nigel Garrett , Cynthia L. Monaco, Philipp Mann, Julia Hutter, Allan C. deCamp, One Dintwe, Georgia Tomaras, Megan Jones, Giuseppe Pantaleo, Song Ding, Olivier Van Der Meeren, Julie McElrath, Larry Corey, James G. Kublin, for the HVTN 108 Study Team MUCOSAL T AND B CELL RESPONSES INDUCED BY ALVAC-HIV/ AIDSVAX B/E LATE BOOST STRATEGIES Alexandra Schuetz , Siriwat Akapirat, Michael A. Eller, Yuwadee Phuang- Ngern, Punnee Pitisutthithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Nittaya Phanuphak, Carlos A. Diazgranados, Jerome H. Kim, Merlin L. Robb, Nelson L. Michael, Robert J. O'Connell, Sandhya Vasan, for the RV306 Study Group CANDIDATE IMMUNOGENS DIFFERENTIALLY ENGAGE HIV BROADLY NEUTRALIZING PLASMA ANTIBODIES Irene Abela , Teja Turk, Nikolas Friedrich, Claus Kadelka, Matthias Gloegl, Brano Ivan, Peter Rusert, Merle Schanz, Roger Kouyos, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study 288 289 290 287

CROI 2020 60 Oral Sessions • Wednesday